Business
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasg
About this update from Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a study evaluating briquilimab in subcutaneous briquilimab in cold urticaria (ColdU) or symptomatic dermographism (SD) during an oral session on Saturday, June 14. Details of the presentations are as follows: Abstract Title: Initial Results from SPOTLIGHT, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Inducible Urticaria (CIndU) Who Remain Symptomatic Despite H-1 Antihistamine TreatmentAbstract Number: 269Session Type/Title: Oral Abstract Session on Clinical Trials (OAS-CT2, Clinical Trials on Dermatology) Presentation Date/Time: June 14, 3:00-4:30pm Abstract Title: A Single Dose of Briquilimab, an Anti-Human c-Kit (CD117)-Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117Abstract Number: 523Session Type/Title: Thematic Poster Session (Biologicals 02)Presentation Date/Time: June 14, 12:00-1:00pm Abstract Title: Briquilimab Demonstrates Rapid, Clinically Meaningful Disease-Control in Adults with Chronic Spontaneous Urticaria (CSU): Updated Results from Phase 1b/2a StudyAbstract Number: 100281Session Type/Title: Flash Talk (L-FT08 Dermatology) Presentation Date/Time: June 15, 12:45-1:45pm Abstract Title: Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117)-Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 MiceAbstract Number: 537Session Type/Title: Thematic Poster Session (Asthma 07),Presentation Date/Time: June 15, 12:45-1:45pm About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that ...
View stock analysis, news, and events for Jasper Therapeutics, Inc.